Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sarasota Memorial Health Care System in Sarasota, Florida, under the supervision of Ralph P. Tufano, MD, MBA, FACS. And the 100th patient was enrolled in August completing enrollment in the study.

Enrollment was completed following an expansion of the study from its original 50-patient design to 100 patients. All patients were enrolled across three U.S. clinical sites — Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine in approximately 12 months.

"Completing enrollment in PRECISE-BTN at double the original patient count is a meaningful milestone for the Company and for symptomatic benign thyroid patients," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. "We are grateful to our investigators, coordinators, and patients for making this possible."

The Company plans to present preliminary data from the PRECISE-BTN study at an upcoming medical society conference, with full data expected upon completion of the study’s 12-month follow-up for all patients.